Resistance of Streptococcus pneumoniae to fluoroquinolones - United States, 1995-1999

Morbidity and Mortality Weekly Report

Volumn 50, Issue 37, 2001, Pages 800-804

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; OFLOXACIN;

ANTIBIOTIC RESISTANCE; ARTICLE; DRUG EFFECT; HUMAN; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

ANTI-INFECTIVE AGENTS; DRUG RESISTANCE, MICROBIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; OFLOXACIN; PNEUMOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

EID: 0035929701     PISSN: 01492195     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000;31:347-82.
2. Campbell GD Jr. Commentary on the 1993 American Thoracic Society guidelines for the treatment of community-acquired pneumonia. Chest 1999;115:14-8.
3. Heffelfinger JD, Dowell SF, Jorgensen H, et al. Management of community-acquired pneumonia in the era of antimicrobial resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 2000;160:1399-408.
4. Richard MP, Aguado AG, Mattina R, Marre R. Sensitivity to sparfloxacin and other antibiotics, of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis strains isolated from adult patients with community-acquired lower respiratory tract infections: a European multicentre study. J Antimicrob Chemother 1998;41:207-14.
5. Odland BA, Jones RN, Verhoef J, Fluit A, Beach ML. Antimicrobial activity of gatifloxacin (AM-1155, CG5501), and four other fluoroquinolones tested against 2,284 recent clinical strains of Streptococcus pneumoniae from Europe, Latin America, Canada, and the United States. Diagn Microbiol Infect Dis 1999;34:315-20.
6. Chen DK, McGeer A, de Azavedo JC, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 1999;341:233-9.
7. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard M7-A5. Wayne, Pennsylvania: National Committee for Clinical Laboratory Standards, 2000.
8. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility tests (M100-S11). Wayne, Pennsylvania: National Committee for Clinical Laboratory Standards, 2001.
9. Jorgensen JH, Weigel LM, Ferraro JM, Swenson JM, Tenover FC. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates, including those with mutations in the gyrA, parC, and parE loci. Antimicrob Agents Chemother 1999;43:329-34.
10. Jorgensen JH, Weigel LM, Swenson JM, Whitney CG, Ferraro JM, Tenover FC. Activities of clinafloxacin, gatifloxacin, gemifloxacin, and trovafloxacin against recent clinical isolates of levofloxacin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 2000;44:2962-8.